Company intelligence / Profile preview

Parvalis Tx

Ownership: Private
Development stage: Other

Overview

Parvalis Tx is a seed-stage drug discovery biotech developing novel oral immunomodulatory small molecules targeting a clinically and commercially validated immune pathway. The company is a spin-out from Trinity College Dublin, founded by Dr William McCormack and Professor Kingston Mills, with funding from Lightstone Ventures, Atlantic Bridge, and Enterprise Ireland. It remains preclinical with no disclosed clinical results yet.

Modalities: Small molecule (novel oral immunomodulatory compounds)
Industry: Biotech

Beyond the preview

Go deeper on Parvalis Tx.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Parvalis Tx.

Explore the full profile